PCOS To PMOS (Polyendocrine Metabolic Ovarian Syndrome) | New Update| Nursing

🔴 Breaking – May 2026 🌸 OBG / Women's Health Nursing

PMOS –
Polyendocrine Metabolic
Ovarian Syndrome

PCOS has been officially renamed PMOS (Polyendocrine Metabolic Ovarian Syndrome) as of May 12, 2026, following a landmark 11-year global consensus process published in The Lancet. Complete nursing notes with pathophysiology, symptoms, Rotterdam criteria, management and high-yield MCQs.

🆕 PCOS → PMOS (May 2026)

📋 Rotterdam Criteria

💊 Full Management

👩‍⚕️ Nursing Care

❓ 14 MCQs

🧠 Mnemonics

🗞️ Official News – May 12, 2026

PCOS Officially Renamed PMOS by Global Consensus

After hearing from 22,000 people — doctors, researchers, patients, and patient advocacy organizations — over 11 years, a landmark global consensus process led by Professor Helena Teede at Monash University, Australia has officially renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). The name change was published in The Lancet and presented at the European Congress of Endocrinology in Prague. More than 56 leading academic, clinical, and patient organisations — including the Endocrine Society — participated. A 3-year transition period is now underway to update clinical guidelines, medical education curricula, and international disease classification systems (ICD).

📰 Source: The Lancet | Endocrine Society | CNN | STAT News | May 12–13, 2026

💡 Definition of PMOS

Polyendocrine Metabolic Ovarian Syndrome (PMOS), formerly known as Polycystic Ovary Syndrome (PCOS), is a complex, chronic, multisystem hormonal and metabolic disorder affecting women of reproductive age. It is characterised by hormonal fluctuations with wide-ranging effects on metabolic health, reproductive health, mental health, skin, and weight. It affects approximately 1 in 8 women (170+ million women worldwide), with an estimated 70% undiagnosed.

🌍

Worldwide Prevalence

170+ Million

Women affected globally

👩

Prevalence Rate

1 in 8

Reproductive-age women

❓

Undiagnosed

~70%

Do not know they have it

🔬

Renamed

May 12, 2026

Published in The Lancet

🏫

Led By

Monash University

Melbourne, Australia

⏳

Transition Period

3 Years

For full implementation

🔄 Why Was PCOS Renamed to PMOS?

❌ Problems with "PCOS"

• The term "polycystic" implied abnormal ovarian cysts — which many patients do NOT actually have
• Focused only on ovaries — missed the BIG PICTURE of a multisystem hormonal disorder
• Reproductive-focused name overlooked metabolic, cardiovascular, and mental health dimensions
• Caused stigma and myth — patients believed they had dangerous cysts
• Led to delayed diagnosis and fragmented care
• Did not capture the endocrine (hormonal) or metabolic nature of the condition
• Doctors focused on fertility, missing cardiovascular/diabetes risk

✅ Why "PMOS" is Better

• Polyendocrine = recognises multiple hormone systems are involved (insulin, androgens, LH/FSH, cortisol)
• Metabolic = highlights insulin resistance, diabetes risk, cardiovascular risk, obesity
• Ovarian = retains ovarian involvement for clinical recognition
• Syndrome = collection of features across multiple body systems
• Reduces stigma — no mention of "cysts"
• Prompts doctors to address metabolic health, not just fertility
• More scientifically accurate and internationally accepted

🧠

What Does PMOS Stand For? – Break It Down

Poly = Multiple / Many

Endocrine = Hormonal system involvement (androgens, insulin, LH/FSH)

Metabolic = Insulin resistance, diabetes risk, cardiovascular risk, obesity

Ovarian = Ovaries are involved (polycystic morphology on ultrasound)

Syndrome = Collection of features — not one single disease

👉 PMOS recognises that this condition is NOT just about cysts or the ovaries — it's a complex HORMONAL + METABOLIC disorder affecting the WHOLE body!

🔬 Pathophysiology of PMOS

The exact cause is unknown, but PMOS involves a complex interaction between genetic predisposition, insulin resistance, androgen excess, and dysregulated HPO (Hypothalamic-Pituitary-Ovarian) axis. Insulin resistance is considered the central driver in most patients.

🧬

Genetic + Environmental Factors

Predisposition + lifestyle

→

📉

Insulin Resistance

Cells don't respond to insulin

→

📈

Hyperinsulinaemia

Compensatory ↑ insulin

→

💛

↑ LH : FSH Ratio

Pituitary dysregulation

→

⚡

↑ Androgen Production

Theca cells overproduce androgens

→

🌸

PMOS Features

Anovulation, PCO morphology, hyperandrogenism

Hormone	Change in PMOS	Effect
Insulin	↑↑ (Hyperinsulinaemia)	Stimulates ovarian theca cells → ↑ androgen production; ↓ SHBG → more free androgens
LH (Luteinising Hormone)	↑ Elevated	Overstimulates theca cells → androgen excess; abnormal LH pulse frequency
FSH (Follicle Stimulating Hormone)	↓ Relatively low / Normal	Follicles start but don't mature fully → arrested follicular development → anovulation
LH:FSH Ratio	>2:1 (normally 1:1)	Classic lab finding in PMOS — reflects hypothalamic-pituitary dysregulation
Androgens (Testosterone, DHEA-S)	↑ Elevated (hyperandrogenism)	Hirsutism, acne, androgenic alopecia, acanthosis nigricans
SHBG (Sex Hormone Binding Globulin)	↓ Decreased	More free (active) androgens circulating → amplifies hyperandrogenism symptoms
Oestrogen	↑ Chronic low-level elevation	Unopposed oestrogen → endometrial hyperplasia → risk of endometrial cancer
Progesterone	↓ Decreased (anovulation)	No corpus luteum formed → no progesterone → irregular cycles
AMH (Anti-Müllerian Hormone)	↑↑ Significantly elevated	Marker of antral follicle count; used in PMOS diagnosis and monitoring

🩺 Clinical Features of PMOS

PMOS is a multisystem disorder. Features span reproductive, metabolic, dermatological, psychological, and cardiovascular systems. Not all features are present in every patient — presentations vary widely.

🧠

Mnemonic – Features of PMOS: "HIM WADE"

Hirsutism (excess hair on face, body)

Irregular periods (oligomenorrhoea / amenorrhoea)

Metabolic syndrome (insulin resistance, obesity)

Weight gain / Obesity (central/abdominal)

Acne (androgen-driven)

Difficulty conceiving (Infertility / anovulation)

Emotional / Mental health (depression, anxiety)

Additional: Alopecia (androgenic), Acanthosis Nigricans, Polycystic ovarian morphology on USG

🌸

Menstrual Irregularities

Most Common Presentation

• Oligomenorrhoea (cycles >35 days) — most common
• Amenorrhoea (absence of periods for ≥3 months)
• Infrequent, irregular, unpredictable periods
• Heavy periods (when they occur)
• Due to chronic anovulation (no egg released = no corpus luteum = no progesterone)

💇

Hyperandrogenism

Androgen Excess Features

• Hirsutism — excess coarse hair on face (upper lip, chin), chest, abdomen (Ferriman-Gallwey score >8)
• Acne (severe, chin and jaw line — hormonal pattern)
• Androgenic Alopecia — thinning/loss of scalp hair (male-pattern baldness)
• Oily skin (seborrhoea)
• Clitoromegaly (rare, severe cases)

⚖️

Metabolic Features

Central to PMOS Name

• Insulin resistance — most common metabolic defect (70–80%)
• Obesity — especially central/abdominal adiposity
• Type 2 diabetes / Pre-diabetes (5–10× increased risk)
• Dyslipidaemia (↑TG, ↓HDL, ↑LDL)
• Metabolic syndrome
• Acanthosis Nigricans — dark velvety skin patches at neck, armpits (sign of insulin resistance)
• Non-alcoholic fatty liver disease (NAFLD)

💔

Cardiovascular Risk

Long-term Risk

• Hypertension
• ↑ Risk of cardiovascular disease and stroke
• Atherosclerosis risk (due to dyslipidaemia + insulin resistance)
• Sleep apnoea — 30× more common in PMOS
• Endometrial cancer risk — 3× higher (unopposed oestrogen)

🧠

Psychological / Mental Health

Highly Prevalent – Often Missed

• Depression — 3× more common than general population
• Anxiety disorders — highly prevalent
• Poor body image and self-esteem
• Eating disorders (binge eating disorder)
• Emotional distress from fertility concerns
• Social withdrawal and reduced quality of life

🤰

Reproductive / Fertility Issues

Anovulatory Infertility

• Anovulation → most common cause of anovulatory infertility
• Subfertility — difficulty conceiving naturally
• Recurrent miscarriage risk (↑)
• Pregnancy complications: GDM, pre-eclampsia, preterm birth
• PMOS is the most common cause of female infertility due to ovulatory dysfunction

📋 Rotterdam Diagnostic Criteria for PMOS

🚨

HIGH-YIELD for NORCET! PMOS is diagnosed using the Rotterdam Criteria (2003) — still the most widely used diagnostic criteria globally. Diagnosis requires at least 2 out of 3 features after excluding other causes of hyperandrogenism.

①

Oligo/Anovulation

Irregular or absent menstrual cycles. Fewer than 8 periods per year (oligomenorrhoea) or absence for >3 months (amenorrhoea). Indicates chronic anovulation.

②

Clinical/Biochemical Hyperandrogenism

Clinical: Hirsutism (Ferriman-Gallwey score >8), acne, alopecia. Biochemical: Elevated serum testosterone or DHEA-S. Indicates androgen excess.

③

Polycystic Ovarian Morphology (PCOM) on USG

Transvaginal ultrasound: ≥12 follicles (2–9 mm) per ovary OR ovarian volume >10 mL. Also: AMH ≥ threshold (increasingly used as alternative to USG).

💚

Diagnosis Rule: At least 2 of 3 Rotterdam criteria must be present + other causes excluded (congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumour, hyperprolactinaemia, thyroid disorders). Other causes must always be ruled out first!

🧠

Mnemonic – Rotterdam Criteria: "OHA" (need 2 of 3)

Oligo/Anovulation (irregular/absent periods)

Hyperandrogenism (clinical or biochemical)

Abnormal USG (polycystic ovarian morphology)

👉 Need 2 out of O, H, A = PMOS diagnosed (after ruling out other causes). Remember "OHA" for Rotterdam!

🔍 Investigations / Diagnosis

Investigation	Finding in PMOS	Purpose
Transvaginal Ultrasound	≥12 follicles (2–9mm) per ovary OR ovarian volume >10 mL	Primary imaging — confirm polycystic ovarian morphology
Serum LH & FSH	LH:FSH ratio >2:1 (or >3:1 in some criteria)	HPO axis dysregulation — classic PMOS pattern
Serum Testosterone	↑ Total testosterone or free testosterone	Biochemical hyperandrogenism confirmation
DHEA-S	May be elevated (adrenal androgen)	Adrenal androgen excess
SHBG	↓ Decreased	Low SHBG → more free active androgens
AMH (Anti-Müllerian Hormone)	↑ Significantly elevated (2–3× normal)	Marker of antral follicle pool; increasingly replacing USG for PCOM diagnosis
Fasting Blood Glucose + Insulin	↑ Fasting insulin; HOMA-IR >2.5	Insulin resistance assessment (HOMA-IR = Homeostatic Model Assessment)
Oral Glucose Tolerance Test (OGTT)	Impaired glucose tolerance or T2DM	Diabetes screening — recommended in all PMOS patients
Fasting Lipid Profile	↑TG, ↓HDL, ↑LDL	Cardiovascular risk assessment
Thyroid Function Tests	Normal (to rule out thyroid cause)	Exclude hypothyroidism as cause of menstrual irregularity
Prolactin	Normal (to rule out hyperprolactinaemia)	Exclude prolactinoma
17-OH Progesterone	Normal (to rule out CAH)	Exclude Congenital Adrenal Hyperplasia
Endometrial Biopsy	Endometrial hyperplasia (if amenorrhoea >1 year)	Rule out endometrial cancer in prolonged anovulation

💊 Management of PMOS

Management is individualised based on the patient's presenting concerns — whether they want pregnancy, management of menstrual irregularity, skin symptoms, or metabolic health. There is no cure — treatment is symptomatic and focused on long-term health outcomes.

🏃 1. Lifestyle Modification – FIRST LINE for ALL patients

🥗

Diet Modifications

• Low glycaemic index (low GI) diet — reduces insulin spikes
• High fibre, whole grains, vegetables, lean protein
• Reduce refined carbohydrates and sugar
• Mediterranean diet — proven to improve PMOS outcomes
• Even 5–10% weight loss significantly improves symptoms
• Anti-inflammatory foods (omega-3 rich foods)

🏋️

Exercise

• Minimum 150 min/week moderate aerobic exercise
• Resistance/strength training — improves insulin sensitivity
• Exercise reduces insulin resistance independent of weight loss
• Regular physical activity improves menstrual regularity
• Yoga and stress-reduction exercises helpful for mental health

🧘

Psychological Support

• Cognitive Behavioural Therapy (CBT) for anxiety and depression
• Mindfulness-based stress reduction
• Support groups and peer counselling
• Address body image concerns non-judgementally
• Routine screening for depression and anxiety

💊 2. Pharmacological Management

Drug	Indication	Mechanism	Key Notes
Metformin	Insulin resistance, Metabolic risk, Irregular cycles	↓ Hepatic glucose output; ↑ insulin sensitivity; ↓ androgen production	Drug of Choice for metabolic features. Also improves menstrual regularity. Start low, go slow. Monitor renal function.
Combined Oral Contraceptive Pill (COCP)	Menstrual regulation, Hyperandrogenism, Acne/Hirsutism (not wanting pregnancy)	Suppresses LH → ↓ androgen production; ↑ SHBG → less free testosterone; Provides progesterone to protect endometrium	First-line for cycle regulation in women not seeking pregnancy. Avoid in smokers >35 yrs. Reduces acne and hirsutism over months.
Clomiphene Citrate (Clomid)	Ovulation induction (wanting pregnancy)	Anti-oestrogen → blocks oestrogen feedback → ↑ FSH → stimulates follicular development	First-line for ovulation induction. 50 mg Day 2–6. Monitor with USG. Risk of multiple pregnancy. Up to 6 cycles.
Letrozole	Ovulation induction (superior to Clomiphene)	Aromatase inhibitor → ↓ oestrogen → ↑ FSH release → follicle development	Now preferred over Clomiphene in many guidelines — higher live birth rates. 2.5–5 mg Day 2–6. Lower multiple pregnancy risk.
Spironolactone	Hirsutism, Acne (anti-androgen)	Androgen receptor blocker; also inhibits aldosterone; reduces 5α-reductase activity	Effective for skin symptoms. MUST use contraception (teratogenic — feminises male fetus). Monitor K⁺ (hyperkalaemia risk). Takes 6–12 months for hair results.
Gonadotrophins (FSH/LH injections)	Ovulation induction — Clomiphene resistant	Direct ovarian stimulation → follicular development	Requires close USG monitoring. High risk of OHSS (Ovarian Hyperstimulation Syndrome) — monitor carefully. Second-line fertility treatment.
GLP-1 Agonists (Semaglutide/Liraglutide)	Obesity-driven PMOS — weight management	↓ Appetite, ↑ insulin secretion, ↓ glucagon → weight loss + improved insulin sensitivity	Emerging evidence in PMOS. Significant weight loss → improved hormonal profile and menstrual regularity.
Inositol (Myo-inositol)	Insulin sensitiser — adjunct treatment	Second messenger of insulin signalling → ↑ insulin sensitivity → ↓ androgens → improved ovulation	Evidence-based supplement. Particularly useful in PMOS. Often combined with D-chiro-inositol. Generally well-tolerated.

🏥 3. Surgical Management

Procedure	Indication	Notes
Laparoscopic Ovarian Drilling (LOD)	Clomiphene-resistant anovulatory infertility in PMOS	Electrocautery/laser creates small holes in ovarian stroma → ↓ androgen-producing theca cells → ↓ LH → spontaneous ovulation restored. Reduces multiple pregnancy risk vs gonadotrophins. Effect lasts ~2 years.
IVF (In Vitro Fertilisation)	Failed ovulation induction; severe infertility	Third-line fertility treatment. PMOS patients at high risk of OHSS. Antagonist protocol preferred. Elective freeze-all embryo strategy reduces OHSS risk.
Bariatric Surgery	Severe obesity-related PMOS (BMI >40 or >35 with comorbidities)	Dramatic weight loss → restored ovulation, improved insulin resistance, reduced androgen levels, resolution of many features. Not first-line — lifestyle + medical therapy first.

⚠️ Long-Term Complications of PMOS

Complication	Risk Level	Reason
Type 2 Diabetes Mellitus	5–10× higher risk	Insulin resistance + pancreatic beta cell dysfunction over time
Cardiovascular Disease	Significantly ↑	Hypertension + dyslipidaemia + insulin resistance + obesity
Endometrial Cancer	3× higher risk	Chronic anovulation → unopposed oestrogen stimulation of endometrium → hyperplasia → cancer
Metabolic Syndrome	Very Common	Central obesity + hypertension + dyslipidaemia + insulin resistance
Depression & Anxiety	3× higher risk	Hormonal imbalance + chronic disease burden + body image concerns
Infertility	Very Common	Anovulation = no egg released = difficulty conceiving
Gestational Diabetes	3× higher risk	Pre-existing insulin resistance worsens in pregnancy
Sleep Apnoea	30× higher risk	Obesity + androgen effects on upper airway muscles
OHSS (Ovarian Hyperstimulation Syndrome)	High risk with gonadotrophins	Exaggerated ovarian response to fertility drugs → ascites, pleural effusion, thrombosis

🚨 OHSS – Ovarian Hyperstimulation Syndrome

🚨

HIGH-YIELD! OHSS is a life-threatening complication of fertility treatment in PMOS patients. PMOS patients are at HIGHEST RISK due to high antral follicle count and high AMH. Recognise and manage early!

Feature	Details
Cause	Excessive ovarian response to gonadotrophins → massive follicular development → fluid shift out of vascular space
Timing	Early OHSS: 3–7 days after HCG trigger. Late OHSS: 10–17 days (if pregnancy occurs)
Features	Abdominal pain and distension, Nausea/vomiting, Ascites, Pleural effusion, Oliguria, Thrombosis risk, Shortness of breath
Severe OHSS	Enlarged ovaries >12 cm, Haemoconcentration (Hct >45%), Hyponatraemia, Acute kidney injury, Thromboembolic events
Management	IV fluids (albumin, not saline), Anticoagulation (LMWH), Avoid HCG (use Lupron trigger), Cabergoline (dopamine agonist — reduces VEGF), Freeze-all embryos (no fresh transfer)

👩‍⚕️ Nursing Management of PMOS

📋

Assessment & Monitoring

• Menstrual history — cycle length, regularity, last menstrual period
• Weight, BMI, waist circumference (central obesity)
• Blood pressure monitoring
• Assess for signs of insulin resistance: acanthosis nigricans, skin tags
• Ferriman-Gallwey score for hirsutism severity
• Screen for depression and anxiety (PHQ-9, GAD-7)
• Fasting blood glucose and lipid profile monitoring

💊

Medication Education

• Metformin: take with food to reduce GI side effects; may cause nausea initially
• COCP: take same time daily; not a contraceptive concern in PMOS (ironic — but needed)
• Clomiphene: day 2–6 of cycle; report visual disturbances immediately
• Spironolactone: reliable contraception MANDATORY; monitor K⁺ levels
• Folic acid 5mg daily — essential if trying to conceive
• Alert about OHSS signs during fertility treatment

🥗

Lifestyle Counselling

• Explain that even 5–10% weight loss dramatically improves symptoms
• Non-judgmental approach to weight discussions
• Low GI diet education: avoid white bread, sugary drinks, processed foods
• 150 mins/week exercise counselling — make it achievable
• Sleep hygiene — screen for sleep apnoea in obese patients
• Smoking cessation (cardiovascular risk reduction)

🧠

Psychological Support

• Validate patient's emotional distress — PMOS is a chronic condition
• Screen regularly for depression and anxiety
• Refer to psychologist/counsellor when needed
• Support around fertility concerns — empathetic approach
• Body image counselling for acne, hirsutism, weight gain
• Connect to PMOS/PCOS support groups

📚

Patient Education

• Explain the new name PMOS and what it means — no dangerous cysts!
• PMOS is manageable with lifestyle + medications — not a life sentence
• Regular long-term follow-up is important
• Endometrial cancer risk — importance of regular periods (or medical protection)
• Annual blood glucose and lipid profile checks
• Fertility counselling — ovulation induction options available

🔄

Long-Term Follow-Up

• Annual fasting glucose / HbA1c — diabetes screening
• Blood pressure monitoring every visit
• Lipid profile annually

BMI and waist circumference monitoring

Mental health screening at every visit

Endometrial protection — ensure regular shedding or progesterone

Cardiovascular risk factor management throughout life

📋 PCOS (Old) vs PMOS (New) – Key Differences for Exams

Feature	PCOS (Old Name)	PMOS (New Name – 2026)
Full Name	Polycystic Ovary Syndrome	Polyendocrine Metabolic Ovarian Syndrome
Named in	1935 (Stein-Leventhal Syndrome originally)	May 12, 2026 (The Lancet)
Focus	Ovaries and cysts (narrow, misleading)	Endocrine + Metabolic + Ovarian (broad, accurate)
Cysts implied?	Yes — "polycystic" implies pathological cysts	No — no mention of cysts (many patients don't have them)
Metabolic recognition	Poor — often overlooked in clinical practice	Central to the name — "metabolic" explicitly mentioned
Who led the change?	N/A	Prof. Helena Teede, Monash University, Australia
Published in	N/A	The Lancet (May 2026)
Transition period	N/A	3 years for full implementation globally

📝 High-Yield MCQs – PMOS / PCOS (NORCET 2026)

Q1. PCOS has been officially renamed as PMOS. What does PMOS stand for?

• A) Polycystic Metabolic Ovarian Syndrome
• B) Primary Metabolic Ovarian Syndrome
• C) Polyendocrine Metabolic Ovarian Syndrome
• D) Polyhormonal Metabolic Ovarian Syndrome

💡 Tip: PMOS = Polyendocrine Metabolic Ovarian Syndrome. The new name was published in The Lancet on May 12, 2026, led by Prof. Helena Teede at Monash University, Australia. It recognises the hormonal (endocrine) AND metabolic dimensions of the condition — not just ovarian/cyst features.

Q2. The Rotterdam Criteria for diagnosing PMOS requires how many of the 3 features?

• A) All 3 features must be present
• B) Only 1 feature required
• C) At least 2 out of 3 features (after excluding other causes)
• D) 2 features only if USG is negative

💡 Tip: Rotterdam Criteria = 2 of 3: (1) Oligo/Anovulation, (2) Hyperandrogenism (clinical or biochemical), (3) Polycystic Ovarian Morphology on USG. Mnemonic: OHA. Must FIRST exclude other causes: CAH, Cushing's, thyroid disorders, hyperprolactinaemia, androgen-secreting tumour.

Q3. The MOST COMMON metabolic defect in PMOS is?

• A) Hypothyroidism
• B) Adrenal insufficiency
• C) Insulin resistance
• D) Hyperprolactinaemia

💡 Tip: Insulin resistance is the CENTRAL and most common metabolic defect in PMOS (present in 70–80%). It drives hyperinsulinaemia → stimulates theca cells → ↑ androgen production → ↓ SHBG → more free androgens. This is why "Metabolic" is now in the name PMOS!

Q4. The DRUG OF CHOICE for metabolic features (insulin resistance) in PMOS is?

• A) Clomiphene Citrate
• B) Spironolactone
• C) Metformin
• D) Combined Oral Contraceptive Pill

💡 Tip: Metformin = Drug of Choice for metabolic features of PMOS (insulin resistance, abnormal glucose, dyslipidaemia). Also improves menstrual regularity and reduces androgens. Clomiphene/Letrozole = ovulation induction. COCP = cycle regulation + hyperandrogenism (not seeking pregnancy). Spironolactone = hirsutism/acne.

Q5. The LH:FSH ratio in PMOS is typically?

• A) 1:2 (FSH dominant)
• B) 1:1 (normal equal ratio)
• C) Greater than 2:1 (LH dominant)
• D) 1:3 (FSH dominant)

💡 Tip: LH:FSH >2:1 (or >3:1 in some criteria) = classic PMOS pattern. ↑LH stimulates theca cells → ↑ androgen production. Relatively ↓FSH → follicles start but don't mature/ovulate (arrested follicular development = "polycystic morphology" on USG). This LH:FSH ratio inversion is a key lab finding!

Q6. The FIRST LINE treatment for ovulation induction in PMOS (patient wanting pregnancy) is currently?

• A) Gonadotrophins (FSH injections)
• B) IVF
• C) Letrozole (Aromatase Inhibitor)
• D) Laparoscopic Ovarian Drilling

💡 Tip: Letrozole (aromatase inhibitor) has now superseded Clomiphene Citrate as first-line ovulation induction in many updated guidelines — better live birth rates and lower multiple pregnancy risk. Clomiphene (Clomid) remains widely used and still taught. Gonadotrophins = second line. LOD = for Clomiphene-resistant patients. IVF = third line.

Q7. Acanthosis Nigricans in a woman with PMOS is a skin sign indicating?

• A) Hyperandrogenism
• B) Thyroid dysfunction
• C) Insulin resistance
• D) Cushing's Syndrome

💡 Tip: Acanthosis Nigricans = dark, velvety, thickened skin patches at neck, armpits, groins = SIGN OF INSULIN RESISTANCE. High insulin levels → stimulate keratinocytes and fibroblasts → skin thickening. Common in obese PMOS patients. Also seen in Type 2 Diabetes and obesity states.

Q8. The MOST COMMON cause of anovulatory infertility in women is?

• A) Hypothyroidism
• B) Premature ovarian failure
• C) PMOS (formerly PCOS)
• D) Hyperprolactinaemia

💡 Tip: PMOS = most common cause of anovulatory infertility in women of reproductive age. Anovulation (failure to release egg) = due to arrested follicular development from LH:FSH imbalance + androgen excess + insulin resistance. Also affects 1 in 8 women = most common endocrine disorder in reproductive-age women.

Q9. Which lab marker has emerged as the primary diagnostic alternative to ultrasound for polycystic ovarian morphology in PMOS?

• A) Serum LH levels
• B) Total testosterone
• C) AMH (Anti-Müllerian Hormone)
• D) FSH levels

💡 Tip: AMH (Anti-Müllerian Hormone) = secreted by granulosa cells of antral follicles. Significantly elevated (2–3× normal) in PMOS. Increasingly used as a marker of antral follicle count and is replacing ultrasound for diagnosing polycystic ovarian morphology in updated criteria. AMH >4–5 ng/mL strongly suggests PMOS.

Q10. Laparoscopic Ovarian Drilling (LOD) in PMOS works by?

• A) Removing all ovarian follicles
• B) Creating AV anastomoses in ovarian blood supply
• C) Destroying androgen-producing theca cells → reducing androgens → restoring LH:FSH balance → ovulation
• D) Directly injecting FSH into the ovary

💡 Tip: LOD = multiple small holes (electrocautery/laser) in ovarian cortex and stroma → destroys theca cells (androgen-producing) → ↓ androgens → ↓ LH → ↑ FSH → follicular maturation → spontaneous ovulation restored. Used for Clomiphene-resistant PMOS. Lower multiple pregnancy risk than gonadotrophins.

Q11. OHSS (Ovarian Hyperstimulation Syndrome) is MOST likely to occur in which patients?

• A) Postmenopausal women on HRT
• B) Women with premature ovarian failure
• C) PMOS patients undergoing fertility treatment with gonadotrophins
• D) Women with endometriosis undergoing IVF

💡 Tip: PMOS patients are at HIGHEST risk of OHSS due to high AMH + high antral follicle count → exaggerated ovarian response to gonadotrophins. Severe OHSS: ascites, pleural effusion, thrombosis, acute kidney injury. Management: albumin, anticoagulation, cabergoline, freeze-all embryos, no HCG trigger (use GnRH agonist trigger instead).

Q12. Long-term risk of ENDOMETRIAL CANCER in PMOS is increased due to?

• A) HPV infection associated with PMOS
• B) High progesterone levels causing endometrial hyperplasia
• C) Chronic anovulation → no corpus luteum → no progesterone → unopposed oestrogen stimulates endometrium
• D) Androgen excess directly causing endometrial mutation

💡 Tip: No ovulation = no corpus luteum = no progesterone. Oestrogen is still produced (peripheral conversion of androgens) → chronically stimulates endometrium without progesterone opposition → endometrial hyperplasia → risk of endometrial cancer (3× higher). Prevention: induce regular periods using COCP or cyclic progesterone.

Q13. The MOST IMPORTANT reason PCOS was renamed PMOS is because?

• A) Cysts are no longer found in patients with this condition
• B) New genetic testing changed the disease classification
• C) The old name was scientifically inaccurate, narrowly focused on ovaries and cysts, missing the broad metabolic and hormonal complexity of the condition
• D) The WHO mandated the change due to new treatment protocols

💡 Tip: The rename addresses the fact that PCOS implied "polycystic ovaries" as the defining feature — but many patients don't have cysts, and the name missed the bigger picture of a complex endocrine + metabolic + multi-system disorder. The new name PMOS ensures doctors address metabolic health, cardiovascular risk, mental health, not just fertility/ovaries.

Q14. A nurse is educating a patient newly diagnosed with PMOS about their condition. Which statement by the nurse is MOST appropriate?

• A) "You have dangerous cysts on your ovaries that need surgery"
• B) "This is purely a reproductive problem, so we will focus only on fertility"
• C) "You cannot conceive naturally with this condition"
• D) "PMOS is a complex hormonal and metabolic condition — with lifestyle changes and medications, symptoms can be well managed and many women with PMOS conceive successfully"

💡 Tip: Key nursing education points: (1) No dangerous cysts — just immature follicles. (2) It's a WHOLE-BODY hormonal + metabolic disorder, not just reproductive. (3) Many women with PMOS conceive with treatment. (4) Lifestyle modification is the most powerful first-line treatment. (5) Long-term metabolic/cardiovascular monitoring is essential.

⚡ Quick Reference – PMOS (Formerly PCOS)

New Name

PMOS (May 12, 2026)

PMOS Full Form

Polyendocrine Metabolic Ovarian Syndrome

Published In

The Lancet + European Endocrinology Congress

Led By

Prof. Helena Teede, Monash University

Prevalence

1 in 8 women (170+ million)

Rotterdam Criteria

2 of 3 – OHA (Mnemonic)

Core Defect

Insulin Resistance

LH:FSH Ratio

>2:1 (LH dominant)

AMH in PMOS

↑↑ Elevated (2–3× normal)

Drug of Choice (metabolic)

Metformin

Ovulation Induction

Letrozole (preferred) / Clomiphene

Hirsutism Drug

Spironolactone (+ contraception!)

Cycle Regulation

COCP (not wanting pregnancy)

Surgical Tx

LOD (Clomiphene resistant)

Endometrial Cancer Risk

3× higher (unopposed oestrogen)

Most Common Complication

Insulin resistance → T2DM

First Line Treatment

Lifestyle modification

OHSS Risk

Highest in PMOS with gonadotrophins

Acanthosis Nigricans

Sign of insulin resistance

Transition Period

3 years for full global implementation